https://www.cslseqirus.us/ 1.0000 2023-10-25 https://www.cslseqirus.us/globalselector 0.5000 2024-08-01 https://www.cslseqirus.us/our-company 0.5000 2024-02-20 https://www.cslseqirus.us/expertise 0.5000 2023-10-25 https://www.cslseqirus.us/products 0.5000 2024-07-24 https://www.cslseqirus.us/careers 0.5000 2026-01-22 https://www.cslseqirus.us/news 0.5000 2023-10-25 https://www.cslseqirus.us/partnering 0.5000 2022-11-04 https://www.cslseqirus.us/contact 0.5000 2023-10-25 https://www.cslseqirus.us/cookie-policy 0.5000 2023-10-25 https://www.cslseqirus.us/privacy-statement 0.5000 2024-04-25 https://www.cslseqirus.us/terms-of-use 0.5000 2022-11-04 https://www.cslseqirus.us/accessibility-statement 0.5000 2022-09-09 https://www.cslseqirus.us/reset-password 0.5000 2019-07-25 https://www.cslseqirus.us/search 0.5000 2019-11-14 https://www.cslseqirus.us/sitemap 0.5000 2019-07-25 https://www.cslseqirus.us/our-company/corporate-responsibility 0.5000 2023-10-25 https://www.cslseqirus.us/our-company/leadership 0.5000 2024-08-06 https://www.cslseqirus.us/our-company/corporate-responsibility/disclosures 0.5000 2022-11-04 https://www.cslseqirus.us/our-company/leadership/roberta-duncan 0.5000 2021-10-01 https://www.cslseqirus.us/our-company/leadership/stephen-marlow 0.5000 2022-11-04 https://www.cslseqirus.us/our-company/leadership/ken-lim 0.5000 2022-11-04 https://www.cslseqirus.us/our-company/leadership/chris-larkins 0.5000 2022-11-04 https://www.cslseqirus.us/our-company/leadership/lorna-meldrum 0.5000 2022-11-04 https://www.cslseqirus.us/our-company/leadership/dave-ross 0.5000 2022-11-04 https://www.cslseqirus.us/our-company/leadership/gregg-sylvester 0.5000 2022-11-04 https://www.cslseqirus.us/our-company/leadership/sharon-mchale 0.5000 2022-11-04 https://www.cslseqirus.us/our-company/leadership/karen-netherton 0.5000 2022-11-04 https://www.cslseqirus.us/our-company/leadership/marcus-de-alwis 0.5000 2022-11-04 https://www.cslseqirus.us/our-company/leadership/judi-badenoch 0.5000 2022-11-17 https://www.cslseqirus.us/our-company/leadership/jon-edelman 0.5000 2023-01-31 https://www.cslseqirus.us/our-company/leadership/paul-davies 0.5000 2024-03-18 https://www.cslseqirus.us/our-company/leadership/chris-thorpe 0.5000 2024-04-01 https://www.cslseqirus.us/our-company/leadership/stefan-merlo 0.5000 2024-07-01 https://www.cslseqirus.us/expertise/influenza 0.5000 2023-11-17 https://www.cslseqirus.us/expertise/influenza/pandemic-response-solutions 0.5000 2022-11-04 https://www.cslseqirus.us/careers/see-yourself-at-seqirus 0.5000 2026-01-23 https://www.cslseqirus.us/careers/discover-our-people 0.5000 2026-01-23 https://www.cslseqirus.us/careers/how-we-care-for-you-at-seqirus 0.5000 2026-01-23 https://www.cslseqirus.us/careers/inclusion-and-belonging 0.5000 2026-01-23 https://www.cslseqirus.us/news/140-million-manufacturing-expansion 0.5000 2019-07-25 https://www.cslseqirus.us/news/seqirus-announces-major-advances-in-pandemic-preparedness 0.5000 2019-07-25 https://www.cslseqirus.us/news/cell-based-seasonal-influenza-vaccines 0.5000 2019-04-12 https://www.cslseqirus.us/news/be-fluent-partnership-shines-spotlight-on-importance-of-flu-prevention-in-seniors 0.5000 2019-07-25 https://www.cslseqirus.us/news/seqirus-announces-next-major-advancement-in-cell-based-influenza-vaccine-technology 0.5000 2019-07-25 https://www.cslseqirus.us/news/seqirus-presents-favorable-outcomes-data-for-adjuvanted-trivalent-influenza-vaccine-fluad 0.5000 2019-09-02 https://www.cslseqirus.us/news/seqirus-presents-data-at-idweek-demonstrating-cell-derived-viruses 0.5000 2019-09-02 https://www.cslseqirus.us/news/seqirus-secures-fda-approval-for-next-generation-cell-based-influenza-vaccine-manufacturing-process 0.5000 2019-09-02 https://www.cslseqirus.us/news/seqirus-receives-fda-approval-of-afluria-quadrivalent-influenza-vaccine 0.5000 2019-09-02 https://www.cslseqirus.us/news/seqirus-donates-influenza-vaccine-for-hurricane-harvey-relief-in-texas 0.5000 2019-09-02 https://www.cslseqirus.us/news/seqirus-is-first-to-market-with-shipment-of-seasonal-influenza-vaccines-for-2016-2017-season 0.5000 2019-09-02 https://www.cslseqirus.us/news/seqirus-receives-fda-approval-of-afluria-quadrivalent-for-six-months-of-age-and-older 0.5000 2019-09-02 https://www.cslseqirus.us/news/new-scientific-data-comparing-circulating-influenza-b-viruses 0.5000 2019-09-06 https://www.cslseqirus.us/news/new-clinical-data-reinforces-the-ability-of-mf59-adjuvanted-seasonal-and-pandemic-influenza-vaccines 0.5000 2019-10-24 https://www.cslseqirus.us/news/seqirus-applauds-the-executive-order-to-accelerate-enhanced-protection-against-influenza-threats 0.5000 2019-11-15 https://www.cslseqirus.us/news/seqirus-releases-first-shipment-for-2019-2020-season 0.5000 2019-11-15 https://www.cslseqirus.us/news/seqirus-begins-shipping-2017-2018-influenza-vaccines 0.5000 2019-11-15 https://www.cslseqirus.us/news/seqirus-begins-shipping-2018-2019-influenza-vaccines-to-the-us-market 0.5000 2019-11-15 https://www.cslseqirus.us/news/covid19-update 0.5000 2020-04-02 https://www.cslseqirus.us/news/the-university-of-queensland-cepi-and-csl-partner-on-covid-19-vaccine-candidate 0.5000 2020-07-29 https://www.cslseqirus.us/news/seqirus-ships-2020-2021-influenza-vaccines-to-us-market 0.5000 2020-07-30 https://www.cslseqirus.us/news/seqirus-presents-new-real-world-evidence-on-relative-effectiveness 0.5000 2020-11-05 https://www.cslseqirus.us/news/seqirus-announces-late-breaking-data-at-idweek-2020 0.5000 2020-10-21 https://www.cslseqirus.us/news/seqirus-presents-first-of-its-kind-study-on-cell-based-quadrivalent-influenza-vaccine 0.5000 2020-11-05 https://www.cslseqirus.us/news/seqirus-real-world-evidence-published 0.5000 2020-11-05 https://www.cslseqirus.us/news/seqirus-presents-new-data-at-eswi-2020-demonstrating-safety-and-immunogenicity 0.5000 2020-12-07 https://www.cslseqirus.us/news/seqirus-presents-new-late-breaking-data-at-eswi-2020 0.5000 2020-12-05 https://www.cslseqirus.us/news/seqirus-presents-real-world-data-for-cell-based-quadrivalent 0.5000 2020-12-09 https://www.cslseqirus.us/news/seqirus-announces-us-fda-approval-of-expanded-age-indication 0.5000 2021-03-05 https://www.cslseqirus.us/news/new-seqirus-data-published-in-vaccines-highlight-effectiveness 0.5000 2021-03-25 https://www.cslseqirus.us/news/new-rwe-flu-65-and-older 0.5000 2021-04-20 https://www.cslseqirus.us/news/study-simultaneous-admin-flu-covid 0.5000 2021-06-21 https://www.cslseqirus.us/news/first-shipment-2021-22 0.5000 2021-07-27 https://www.cslseqirus.us/news/safety-data-seasonal-pregnancy 0.5000 2021-07-30 https://www.cslseqirus.us/news/seqirus-invests-in-self-amplifying-messenger-rna-technology 0.5000 2021-08-19 https://www.cslseqirus.us/news/seqirus-publishes-new-real-world-evidence 0.5000 2021-08-23 https://www.cslseqirus.us/news/data-supports-cell-based-flu-vaccine-in-children 0.5000 2021-08-23 https://www.cslseqirus.us/news/seqirus-presents-new-rwe-flu-vaccines-at-idweek 0.5000 2021-09-29 https://www.cslseqirus.us/news/seqirus-awarded-us-government-contract-for-two-influenza-vaccines 0.5000 2021-10-04 https://www.cslseqirus.us/news/seqirus-receives-fda-approval-for-flucelvax-quadrivalent-for-children-6-months-and-older 0.5000 2021-10-15 https://www.cslseqirus.us/news/seqirus-announces-new-facility-supporting-research-and-development-of-influenza-vaccine-technology 0.5000 2022-02-07 https://www.cslseqirus.us/news/seqirus-receives-fda-approval-for-fluad-quadrivalent-for-adults-65-years-and-older 0.5000 2022-02-16 https://www.cslseqirus.us/news/update-on-cdc-advisory-committee-immunization-practices-review-enhanced-flu-vaccines-adults-65-plus 0.5000 2022-03-04 https://www.cslseqirus.us/news/fluad-quadrivalent-is-a-preferentially-recommended-influenza-vaccine-for-adults-65-and-older 0.5000 2022-06-23 https://www.cslseqirus.us/news/seqirus-begins-shipping-portfolio-of-innovative-influenza-vaccines-for-the-2022-23-us-season 0.5000 2022-07-11 https://www.cslseqirus.us/news/seqirus-to-highlight-commitment-to-influenza-protection-with-data-presentations-at-options-xi 0.5000 2022-09-13 https://www.cslseqirus.us/news/new-rwd-presented-options-xi-show-influenza-vaccines-can-reduce-burden-of-seasonal-influenza 0.5000 2022-09-26 https://www.cslseqirus.us/news/new-data-at-options-xi-conference-highlight-burden-of-seasonal-influenza-on-health-systems 0.5000 2022-09-26 https://www.cslseqirus.us/news/csl-seqirus-us-government-award-to-manufacture-and-assess-influenza-a-h5n8-pre-pandemic-vaccine 0.5000 2022-10-06 https://www.cslseqirus.us/news/csl-enters-licensing-agreement-arcturus-therapeutics-next-gen-mrna-vaccine-technology 0.5000 2022-11-01 https://www.cslseqirus.us/news/csl-announces-closing-of-global-collaboration-and-licensing-agreement-with-arcturus-therapeutics 0.5000 2022-12-12 https://www.cslseqirus.us/news/seqirus-announces-us-fda-approval-of-pandemic-influenza-vaccine 0.5000 2022-12-16 https://www.cslseqirus.us/news/seqirus-presents-evidence-of-seasonal-influenza-vaccine-effectiveness-at-isirv 0.5000 2022-12-16 https://www.cslseqirus.us/news/nejm-study-cell-based-quadrivalent-influenza-vaccine-efficacy-in-children 0.5000 2022-12-16 https://www.cslseqirus.us/news/seqirus-presents-new-data-at-eswi-8th-virtual-conference 0.5000 2022-12-16 https://www.cslseqirus.us/news/fda-approves-multi-dose-vial-presentation-for-audenz 0.5000 2022-12-16 https://www.cslseqirus.us/news/seqirus-and-us-gov-renew-multi-year-agreement-for-influenza-pandemic-preparedness-and-response 0.5000 2022-12-16 https://www.cslseqirus.us/news/seqirus-completes-$156-million-expansion-to-hsp-manufacturing-facility 0.5000 2022-12-16 https://www.cslseqirus.us/news/csl-announces-positive-preclinical-data-for-self-amplifying-messenger-rna-flu-vaccine-candidates 0.5000 2022-12-16 https://www.cslseqirus.us/news/seqirus-holly-springs-manufacturing-facility-designated-by-us-government-as-pandemic-ready 0.5000 2022-12-16 https://www.cslseqirus.us/news/csl-seqirus-begins-shipping-portfolio-of-innovative-influenza-vaccines-for-2023-24-us-season 0.5000 2023-07-17 https://www.cslseqirus.us/news/csl-seqirus-announces-third-us-government-award-in-relation-to-influenza-a-h5n8-candidate-vaccine 0.5000 2023-08-28 https://www.cslseqirus.us/news/csl-seqirus-presents-rwe-at-eswi-demonstrating-impact-of-influenza-vaccination-campaigns 0.5000 2023-09-19 https://www.cslseqirus.us/news/idweek-2023-demonstrates-public-health-benefit-cost-savings-cell-based-and-adjuvanted-flu-vaccines 0.5000 2023-10-11 https://www.cslseqirus.us/news/csl-seqirus-to-remove-byamagata-influenza-virus-strain-from-portfolio-of-influenza-vaccines 0.5000 2024-02-08 https://www.cslseqirus.us/news/csl-seqirus-fully-prepared-to-implement-fdas-tiv-strain-selection-for-202425-us-season 0.5000 2024-03-06 https://www.cslseqirus.us/news/recently-published-rwe-study-shows-effectiveness-of-cell-based-quad-flu-vaccine-over-3-seasons 0.5000 2024-05-02 https://www.cslseqirus.us/news/csl-seqirus-announces-us-government-award-in-response-to-avian-influenza 0.5000 2024-05-30 https://www.cslseqirus.us/news/csl-seqirus-begins-shipping-its-portfolio-of-influenza-vaccines-for-the-2024-25-flu-season 0.5000 2024-07-09 https://www.cslseqirus.us/news/csl-seqirus-announces-fifth-barda-award-in-response-to-avian-influenza 0.5000 2024-09-25 https://www.cslseqirus.us/news/csl-seqirus-presents-real-world-evidence-at-options-xii-conference 0.5000 2024-10-01 https://www.cslseqirus.us/news/csl-seqirus-announces-sixth-barda-award-in-response-to-avian-influenza 0.5000 2024-10-04 https://www.cslseqirus.us/news/csl-seqirus-presents-data-at-idweek-2024 0.5000 2024-10-16 https://www.cslseqirus.us/news/new-data-presented-at-idweek-2024 0.5000 2024-10-18 https://www.cslseqirus.us/news/csl-seqirus-commences-shipping-its-portfolio-of-influenza-vaccines 0.5000 2025-07-14 https://www.cslseqirus.us/news/recent-rwe-data-show-cell-based-influenza-vaccines-offer-20-percent-greater-protection 0.5000 2025-10-21 https://www.cslseqirus.us/contact/report-an-adverse-event 0.5000 2023-10-25 https://www.cslseqirus.us/contact/media-contacts 0.5000 2023-10-25